Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Aimee Lee Lucas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0341-4826; OpenAlex author ID A5018088794. Sources: ClinicalTrials.gov.

Their work

Papers
43 (first author 7, last author 15)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
116
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 3 papers, 1 trial · 2014: 2 papers · 2015: none · 2016: 5 papers · 2017: 2 papers · 2018: none · 2019: 5 papers · 2020: 3 papers · 2021: 5 papers · 2022: 9 papers · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper

Papers 43

  1. Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2025.08.034↗
  2. Antibiotic treatment and survival in patients with resected, early-stage pancreatic ductal adenocarcinoma receiving chemotherapy. Last author DOI 10.1093/jncics/pkaf024↗
  3. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  4. A High Performing Biomarker Signature for Detecting Early-Stage Pancreatic Ductal Adenocarcinoma in High-Risk Individuals. First author DOI 10.3390/cancers17111866↗
  5. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  6. Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. Last author DOI 10.1001/jamanetworkopen.2023.4254↗
  7. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  8. Glycemic Changes and Weight Loss Precede Pancreatic Ductal Adenocarcinoma by up to 3 Years in a Diverse Population. Last author DOI 10.1016/j.cgh.2021.07.046↗
  9. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  10. Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals. Last author DOI 10.1016/j.hoc.2022.06.004↗
  11. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Co-author DOI 10.1053/j.gastro.2021.10.014↗
  12. Use of endoscopic ultrasound for pancreatic cancer from 2000 to 2016. Last author DOI 10.1055/a-1608-0856↗
  13. Celiac Plexus Neurolysis Is Associated With Decreased Survival in Patients With Pancreatic Cancer: A Propensity Score Analysis. Last author DOI 10.1097/mpa.0000000000001992↗
  14. Response to "re: Celiac Plexus Neurolysis Is Associated With Decreased Survival in Patients With Pancreatic Cancer. Pancreas. 2022;51:153-158". Co-author DOI 10.1097/mpa.0000000000002157↗
  15. Opioid Prescription Is Associated With Increased Survival in Older Adult Patients With Pancreatic Cancer in the United States: A Propensity Score Analysis. Last author DOI 10.1200/op.21.00488↗
  16. Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study. Co-author DOI 10.14309/ctg.0000000000000468↗
  17. Trends in performance of ERCP among patients with surgically unresectable pancreatic cancer: a Survival, Epidemiology and End Results-Medicare database study. First author DOI 10.1016/j.gie.2021.03.998↗
  18. Beta-blockers have no impact on survival in pancreatic ductal adenocarcinoma prior to cancer diagnosis. Last author DOI 10.1038/s41598-020-79999-0↗
  19. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  20. Genetic Variants in Patients With a Family History of Pancreatic Cancer: Impact of Multigene Panel Testing. Last author DOI 10.1097/mpa.0000000000001804↗
  21. Bisphosphonate Use Does Not Impact Survival in Patients with Pancreatic Cancer: A Propensity Score Matching Analysis. Last author DOI 10.5009/gnl20297↗
  22. Surveillance of high-risk individuals for pancreatic cancer with EUS and MRI: A meta-analysis. Last author DOI 10.1016/j.pan.2020.10.025↗
  23. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Co-author DOI 10.1136/gutjnl-2019-319352↗
  24. Correction: Management of patients with increased risk for familial pancreatic cancer: updated recommendations for the international cancer of the pancreas scr… Co-author DOI 10.1136/gutjnl-2019-319352corr1↗
  25. Screening for Pancreatic Cancer Co-author DOI 10.1001/jama.2019.9690↗
  26. Surveillance for pancreatic cancer in high-risk individuals. Co-author DOI 10.1002/bjs5.50180↗
  27. Familial Pancreatic Ductal Adenocarcinoma. First author DOI 10.1016/j.ajpath.2018.06.026↗
  28. Preoperative Endoscopic Retrograde Cholangiopancreatography Is Not Associated With Increased Pancreatic Cancer Mortality. Last author DOI 10.1016/j.cgh.2018.11.056↗
  29. Age, socioeconomic features, and clinical factors predict receipt of endoscopic retrograde cholangiopancreatography in pancreatic cancer. Last author DOI 10.4253/wjge.v11.i2.133↗
  30. Self-Reported Questionnaire Detects Family History of Cancer in a Pancreatic Cancer Screening Program. Co-author DOI 10.1007/s10897-016-0057-4↗
  31. Familial Pancreatic Cancer and the Future of Directed Screening. First author DOI 10.5009/gnl16414↗
  32. Adherence to World Cancer Research Fund/American Institute for Cancer Research recommendations and pancreatic cancer risk. Co-author DOI 10.1016/j.canep.2015.10.026↗
  33. Global Trends in Pancreatic Cancer Mortality From 1980 Through 2013 and Predictions for 2017. Co-author DOI 10.1016/j.cgh.2016.05.034↗
  34. Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis. Last author DOI 10.1038/ajg.2016.288↗
  35. Dietary total antioxidant capacity and pancreatic cancer risk: an Italian case-control study. Co-author DOI 10.1038/bjc.2016.114↗
  36. The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer. Last author DOI 10.5009/gnl15451↗
  37. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Co-author DOI 10.1002/cncr.28662↗
  38. Absence of pancreatic intraepithelial neoplasia predicts poor survival after resection of pancreatic cancer. First author DOI 10.1097/mpa.0000000000000161↗
  39. The prevention and genetics of pancreatic cancer: a programmatic approach. Co-author DOI 10.1007/978-1-62703-287-2_10↗
  40. Evidence for treatment and survival disparities by age in pancreatic adenocarcinoma: a population-based analysis. First author DOI 10.1097/mpa.0b013e31825f3af4↗
  41. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesion… Co-author DOI 10.1158/1078-0432.ccr-12-3020↗
  42. Incidence of subsequent pancreatic adenocarcinoma in patients with a history of nonpancreatic primary cancers. Co-author DOI 10.1002/cncr.26414↗
  43. Screening and detection of pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. First author PMID 21737887↗

Trials 1

  1. Pancreas Registry and High Risk Registry Principal investigator NCT02775461↗

Closest collaborators

The 25 strongest of 116 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haley M. Zylberberg · 7 shared papers, 2021–2023 · strength 1.25
  2. Randall E. Brand · 9 shared papers, 2019–2026 · strength 1.18
  3. Fay Kastrinos · 9 shared papers, 2019–2026 · strength 1.09
  4. Sunil Amin · 10 shared papers, 2012–2022 · strength 1.09
  5. Sheila D. Rustgi · 7 shared papers, 2019–2022 · strength 1.00
  6. Diane M. Simeone · 7 shared papers, 2020–2026 · strength 0.95
  7. Bryson W. Katona · 6 shared papers, 2021–2026 · strength 0.92
  8. Satish Nagula · 5 shared papers, 2019–2022 · strength 0.79
  9. Salvatore Paiella · 6 shared papers, 2019–2026 · strength 0.73
  10. Arielle J. Labiner · 3 shared papers, 2022–2025 · strength 0.73
  11. Paolo Boffetta · 8 shared papers, 2016–2021 · strength 0.70
  12. Elena M. Stoffel · 6 shared papers, 2019–2024 · strength 0.59
  13. Thomas Charles King · 3 shared papers, 2022–2026 · strength 0.59
  14. Jessica N. Everett · 4 shared papers, 2021–2026 · strength 0.56
  15. Sonia S. Kupfer · 4 shared papers, 2021–2026 · strength 0.56
  16. George Zogopoulos · 4 shared papers, 2021–2026 · strength 0.56
  17. Julie Earl · 4 shared papers, 2022–2024 · strength 0.49
  18. Raymond Couric Wadlow · 3 shared papers, 2023–2026 · strength 0.48
  19. Alfredo Carrato · 5 shared papers, 2020–2022 · strength 0.48
  20. Deirdre Jill Cohen · 2 shared papers, 2023–2025 · strength 0.47
  21. Keith Magnus Sigel · 2 shared papers, 2023–2025 · strength 0.47
  22. Daniel Jeremy Fulop · 2 shared papers, 2023–2025 · strength 0.47
  23. Daniel C. Chung · 4 shared papers, 2021–2024 · strength 0.47
  24. Norma Alonzo Palma · 2 shared papers, 2025–2026 · strength 0.45
  25. Lisa A. Ford · 2 shared papers, 2025–2026 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.